The Promise of In Vivo CAR T: Expanding Access Through Off-the-Shelf Innovation

EP: 1.iMMagine-1: Anito-Cel Shows Efficacy in R/R Multiple Myeloma

EP: 2.Safety and Outpatient Potential of Anito-Cel in Multiple Myeloma

EP: 3.Exploring CAR T-Cell Therapy Efficacy in Earlier Vs Later Lines of Therapy

EP: 4.Linking T-Cell Composition to CAR T Efficacy in Multiple Myeloma

EP: 5.Sequencing CAR T-Cell Therapy in the Evolving Myeloma Treatment Landscape

EP: 6.Teclistamab-Daratumumab Outperforms Standard of Care for R/R Multiple Myeloma

EP: 7.MajesTEC-3 and the Future of Combination Regimens in Multiple Myeloma

EP: 8.Early Data Show Feasibility of In Vivo CAR T Therapy in Multiple Myeloma

Now Viewing

EP: 9.The Promise of In Vivo CAR T: Expanding Access Through Off-the-Shelf Innovation

EP: 10.Sequencing, Real-World Evidence, and Unmet Needs: Key Immunotherapy Insights From ASH 2025 in Multiple Myeloma

This interview discusses data on KLN-1010, an investigational in vivo, off-the-shelf CAR T approach presented at ASH 2025, and its potential to meaningfully expand patient access to cellular therapy in multiple myeloma. Unlike conventional autologous CAR T treatments, which require T-cell collection, complex manufacturing, lymphodepleting chemotherapy, and prolonged coordination, KLN-1010 is has potential to simplify and accelerate the treatment process.

A central theme of the discussion is access. By eliminating or substantially reducing the need for lymphodepletion, individualized manufacturing, and prolonged wait times, in vivo CAR T therapy could allow patients to receive treatment much faster. Shorter time to therapy may be particularly important in myeloma, where disease can progress rapidly while patients wait for CAR T production. Reducing these logistical barriers could also lower overall costs and decrease the physical and emotional burden on patients during treatment preparation.

Toxicity remains a critical consideration in determining how broadly this approach can be adopted. The interview emphasizes that widespread access will depend not only on feasibility but also on whether toxicities are manageable and do not routinely require hospitalization. If safety remains favorable, KLN-1010 could be delivered in a wider range of clinical settings, including community hospitals, rather than being limited to highly specialized academic centers.

The findings are also framed within the broader movement toward scalable cellular therapies. Currently, only an estimated 10% to 20% of eligible patients with multiple myeloma ultimately receive CAR T-cell therapy, due to logistical, geographic, and systemic barriers. An off-the-shelf, in vivo CAR T platform could dramatically change this landscape by enabling more centers to offer cellular therapy closer to home. Overall, the data on KLN-1010 suggest a potential paradigm shift toward simpler, more accessible CAR T strategies that could reach a much larger patient population worldwide.